Diabetes Type I
Clinical studies are evaluating Mesenchymal Stem Cells (MSCs) in Type 1 diabetes, focusing on how they may influence immune pathways and help preserve pancreatic function.
Type 1 diabetes is an autoimmune disease in which glutamic acid decarboxylase (GAD) is a major auto-antigen targeted by the immune system and thereby destroys insulin-producing beta cells in the pancreas. This leads to insulin deficiency, high blood sugar and death if untreated. Even if adedquately treated long-term complications often arise affecting multiple organ-systems of the body being an important contributor to morbidity. MSC trials are still early and primarily exploratory, but they are contributing to the broader field of autoimmune and metabolic disease research.
Clinical Trials